[1] Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease[J]. The Lancet, 2003, 361: 2059-2067. [2] Liu F, Calhoun B, Alam MS, et al. Case report: a synonymous VHL mutation (c.414A>G, p.Pro138Pro) causes pathogenic familial hemangioblastoma through dysregulated splicing[J]. BMC Med Genet, 2020, 21: 42.doi:10.1186/s12881-020-0976-7. [3] Lenglet M, Robriquet F, Schwarz K, et al. VHL Identification of a new exon and complex splicing alterations in familial erythrocytosis or von Hippel-Lindau disease[J]. Blood, 2018, 132: 469-483. [4] Flores SK, Cheng Z, Jasper AM, et al. A synonymous VHL variant in exon 2 confers susceptibility to familial pheochromocytoma and von Hippel-Lindau disease[J]. J Clin Endocrinol Metab, 2019, 104: 3826-3834. [5] Hascoet P, Chesnel F, Jouan F, et al. The pVHL(172) isoform is not a tumor suppressor and up-regulates a subset of pro-tumorigenic genes including TGFB1 and MMP13[J]. Oncotarget, 2017, 8: 75989-76002. [6] Chesnel F, Hascoet P, Gagné JP, et al. The von Hippel-Lindau tumour suppressor gene: uncovering the expression of the pVHL172 isoform[J]. Br J Cancer, 2015, 113: 336-344. [7] Flores SK, Cheng Z, Jasper AM, et al. A synonymous VHL variant in exon 2 confers susceptibility to familial pheochromocytoma and von Hippel-Lindau disease[J]. J Clin Endocrinol Metab, 2019, doi:10.1210/jc.2019-00235. [8] Supek F, Miñana B, Valcárcel J, et al. Synonymous mutations frequently act as driver mutations in human cancers[J]. Cell, 2014, 156: 1324-1335. [9] Jayasinghe RG, Cao S, Gao Q, et al. Systematic analysis of splice-site-creating mutations in cancer[J]. Cell Rep, 2018, 23: 270-281.e273.doi:10.1016/j.celrep.2018.03.052. [10] Xiong HY, Alipanahi B, Lee LJ, et al. RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease[J]. Science, 2015, 347: 1254806. doi:10.1126/science.1254806. [11] Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientific review[J]. Eur J Hum Genet, 2011, 19: 617-623. [12] Eisenhofer G, Lenders JW, Linehan WM, et al. Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2[J]. N Engl J Med, 1999, 340: 1872-1879. |